MedTrace Logo

Estradiol and Stress Reactivity in Women

NCT06204016 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 74

Last updated 2024-03-08

No results posted yet for this study

Summary

Stress reactivity and prevalence of stress related diseases differ between pre- and postmenopausal women. Thus, hormonal fluctuations may present a general vulnerability factor for stress-related diseases. Especially, the gonadal hormone estradiol (E2) seems to modulate the activity of stress related brain areas. The hippocampus and prefrontal areas control the amygdala's response to stress, and E2 may directly modulate the activity, connectivity and structure of these areas. In premenopausal women E2 seems to reduce stress reactivity. However, in postmenopausal women, who no longer produce E2 from the ovaries, E2 seem to increase stress reactivity. With the proposed study the investigators want to directly test E2's modulating effects (disentangled from other gonadal hormones) on stress reactivity of premenopausal women during their early follicular phase, and postmenopausal women by subjecting both groups of women to a psychosocial stress task in a neuroimaging environment.

Conditions

  • Stress vs. Control
  • Estradiol vs. Placebo

Interventions

DRUG

Estradiol Valerate

To elevate estradiol levels each woman will receive 12mg on two consecutive days (total 24mg) of estradiol valerate (Progynova21©)

DRUG

Placebo

Placebo tablets will be administered as placebo-controlled condition (P-Tabletten White 7mm, Lichtenstein)

Sponsors & Collaborators

  • University Hospital Tuebingen

    collaborator OTHER

  • German Research Foundation

    collaborator OTHER

  • Uppsala University

    collaborator OTHER

  • International Research Training Group 2804

    lead OTHER

Principal Investigators

  • Birgit Derntl, Prof. · Departement of Psychiatry & Psychotherapy

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-03-07
Primary Completion
2025-07-31
Completion
2025-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06204016 on ClinicalTrials.gov